Hydroxocobalamin Injection Shortage: Teva Pharmaceuticals Reports Supply Issues
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA has reported a current shortage of Hydroxocobalamin Injection due to active ingredient supply issues, with Teva Pharmaceuticals currently listing the product as unavailable.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Hydroxocobalamin.
What's in Shortage
Hydroxocobalamin Injection (Brand Name: HYDROXOCOBALAMIN) is currently listed in a shortage status. This medication, which falls under the therapeutic category of "Other," is provided in an injection dosage form. The specific presentation affected is the 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30).
Which Manufacturers Are Affected
The following manufacturer is currently reporting supply issues for this medication:
- Teva Pharmaceuticals USA, Inc.
- Status: Unavailable
- Notes: Estimated availability is currently To Be Determined (TBD).
- Contact Information: 800-545-8800
Why There's a Shortage
According to the FDA database, the reason for this shortage is a shortage of an active ingredient required for the production of the medication.
What Patients Should Do
If you are prescribed Hydroxocobalamin Injection, it is important to take proactive steps to manage your treatment:
- Consult your healthcare provider: Discuss this shortage with your doctor to determine the best course of action for your specific health needs. Do not discontinue or change your medication without professional medical advice.
- Speak with your pharmacist: Your pharmacist can provide information on current stock levels or potential timelines for when the medication might be back in stock.
- Contact the manufacturer: You may contact Teva Pharmaceuticals directly at 800-545-8800 for the most up-to-date information regarding their supply status.
Source
This information is based on the FDA Drug Shortage Database.
- Initial Posting Date: 11/04/2024
- Last Updated: 02/02/2026
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.